BRCA gene structure and function in tumor suppression: a repair-centric perspective
- PMID: 20164689
- DOI: 10.1097/PPO.0b013e3181cf0204
BRCA gene structure and function in tumor suppression: a repair-centric perspective
Abstract
Germline mutations in the BRCA1 and BRCA2 genes are characterized by deficient repair of DNA double-strand breaks by homologous recombination. Defective DNA double-strand break repair has been not only implicated as a key contributor to tumorigenesis in mutation carriers but also represents a potential target for therapy. The transcriptional similarities between BRCA1-deficient tumors and sporadic tumors of the basal-like subtype have led to the investigation of homologous recombination repair-directed therapy in triple-negative tumors, which demonstrates overlap with the basal-like subtype. We broaden the scope of this topic by addressing a "repair-defective" rather than "BRCA1-like" phenotype. We discuss structural and functional aspects of key repair proteins including BRCA1, BRCA2, BRCA1 interacting protein C-terminal helicase 1, and partner and localizer of BRCA2 and describe the phenotypic consequences of their loss at the cellular, tissue, and organism level. We review potential mechanisms of repair pathway dysfunction in sporadic tumors and address how the identification of such defects may guide the application of repair-directed therapies.
Similar articles
-
Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.PLoS One. 2020 Sep 30;15(9):e0239197. doi: 10.1371/journal.pone.0239197. eCollection 2020. PLoS One. 2020. PMID: 32997669 Free PMC article.
-
Therapeutic exploitation of tumor cell defects in homologous recombination.Anticancer Agents Med Chem. 2008 May;8(4):448-60. doi: 10.2174/187152008784220267. Anticancer Agents Med Chem. 2008. PMID: 18473729 Review.
-
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.Breast Cancer Res Treat. 2015 Feb;150(1):81-90. doi: 10.1007/s10549-015-3306-6. Epub 2015 Feb 19. Breast Cancer Res Treat. 2015. PMID: 25690937 Free PMC article.
-
PALB2 is an integral component of the BRCA complex required for homologous recombination repair.Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7155-60. doi: 10.1073/pnas.0811159106. Epub 2009 Apr 15. Proc Natl Acad Sci U S A. 2009. PMID: 19369211 Free PMC article.
-
Targeting the DNA repair defect of BRCA tumours.Curr Opin Pharmacol. 2005 Aug;5(4):388-93. doi: 10.1016/j.coph.2005.03.006. Curr Opin Pharmacol. 2005. PMID: 15955736 Review.
Cited by
-
Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer.Oncol Lett. 2018 Mar;15(3):2855-2862. doi: 10.3892/ol.2017.7637. Epub 2017 Dec 19. Oncol Lett. 2018. PMID: 29456719 Free PMC article.
-
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.PLoS One. 2013 Nov 6;8(11):e77543. doi: 10.1371/journal.pone.0077543. eCollection 2013. PLoS One. 2013. PMID: 24223121 Free PMC article.
-
Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations.Discov Oncol. 2023 Jun 23;14(1):110. doi: 10.1007/s12672-023-00732-0. Discov Oncol. 2023. PMID: 37351713 Free PMC article. Review.
-
EZH2-mediated epigenetic repression of DNA repair in promoting breast tumor initiating cells.Breast Cancer Res. 2011 May 25;13(3):309. doi: 10.1186/bcr2871. Breast Cancer Res. 2011. PMID: 21672285 Free PMC article.
-
Genistein Prevents BRCA1 CpG Methylation and Proliferation in Human Breast Cancer Cells with Activated Aromatic Hydrocarbon Receptor.Curr Dev Nutr. 2017 May 19;1(6):e000562. doi: 10.3945/cdn.117.000562. eCollection 2017 Jun. Curr Dev Nutr. 2017. PMID: 29955703 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous